Pharm Sci 1 test 1

The flashcards below were created by user alpharmgirl on FreezingBlue Flashcards.

  1. Diuretics: Osmotics
  2. Diuretics: CA Inhibitors
  3. Diuretics: Loops
    • Furosemide
    • Bumetamide
    • Torsemide
    • Ethacrynic Acid
  4. Diuretics: Thiazides
    • HCTZ
    • Chlorthalidone
    • Indapamide
    • Metolazone
  5. Diuretics: Collecting Duct
    • Amiloride
    • Triamterene
    • Eplerenone
    • Spironolactone
  6. Diuretic Braking: Steady State
    activation of RAAS and SNS to counterbalance diuretic (to avoid losing too much volume/pressure)
  7. CA Inhibitors: SOA
  8. CA Inhibitors: MOA
    • reduce NA reabsorption by preventing reabsorption of BICARB
    • INCREASE excretion of BICARB, NA, K, urine pH
    • DECREASE plasma pH
    • *metabolic acidosis risk
  9. CA Inhibitors: Uses
    • Glaucoma (high aqueous humor = HIGH [CA]
    • ICU Tx metabolic alkalosis (excessive loops) **monitor pH for CHF
    • Acute Mt. Sickness- pulmonary edema
  10. Osmotic Diuretics: MOA
    • Freely filtered at glomerulus and NOT reabsorbed!
    • Exerts osmotic force WITHIN tubule, reducing movement of water out of tubule (and Na)***does not effect permeability of anything else.
  11. Osmotic Diuretics: SOA
  12. Osmotic Diuretics: Uses
    • Head Trauma (change in osm gradient of blood...water leaves neurons and goes into blood to decrease pressure)
    • Reduce IOP
  13. Loops: MOA
    • Targets Na/K/Cl symporter, resulting in higher osm in lumen. **REVERSIBLE
    • Transports Na out of the filtrate, thereby diluting it before it is delivered to the DCT.
    • HIGH K excretion due to Na load presented to the collecting duct activates RAAS in the DCT
  14. Loops: SOA
    • TAL/LOH
    • TAL is impermeable to water!
    • "High Ceiling Diuretics"
  15. Loops: Voltage
    apical side more positive. blocking K/Na/Cl symporter increases excretion. this abolition of transepithelial potential difference prevents abs of Mg and Ca
  16. Loops: Drug interactions
    Anything affecting renal blood flow (NSAIDS) can decrease loop effectiveness.
  17. Loops: Adverse Effects
    • Hyponatremia/volume depletion
    • Hypokalemia (causing cardiac arrhythmia)
    • Hypomagnesia (card. arr)
    • Ototoxicity (at high dose/long term)*reversible
  18. Loops: Uses
    • Edema (associated with heart failure)
    • HT
    • ARF (increased flow=flush deposits in kidney)
  19. Thiazides: SOA
  20. Thiazides: MOA
    • inhibits Na/Cl symporter in DCT
    • EXCRETION Na and Cl
    • REABSORPTION Ca (osteoblasts stimulated)
  21. Thiazides: Adverse Effects
    • DECREASED tolerance of  glucose (unmask DM...decreased K=decrease insulin need= increased blood glucose)
    • Arrythmias ( hypokalemia)
    • Increased LDL and TGs

    INEFFECTIVE at GFR<30-40 ml/min
  22. Thiazides: Drug Interactions
    • Potentially lethal interaction: QUINIDINE (due to hypokalemia and reduced elim of this drug)
    • ***prolongs QT interval
    • Additive effects with A/H agents

  23. Thiazides: Uses
    • HT: only class that causes VD, alters pressure-natriuresis curve: as Pressure increases, Sodium excretion increases
    • CHF: (decrease volume)
    • Nephrogenic diabetes insipidus: (loss of response to ADH...increase urine output with no regulation....lowers amt of fluid reaching DCT ***MECHANISM UNCLEAR
  24. Potassium Sparing Diuretics: SOA
    collecting duct
  25. K Sparing: MOA
    • Inhibits the ENaC (competitive); by inhibiting the reabsorption of Na in the Cd, K excretion is reduced (Na reabs is 'balanced' by K excretion)
    • Small INCREASE Na Cl excretion
    • Small DECREASE K H Ca Mg excretion
  26. K Sparing: Adverse Effects
    Hyperkalemia (no cardiac pts. or K supps)
  27. K Sparing: Uses
    HT (not stand alone therapy)
  28. What metabolic disturbance is acetazolamide often used to treat in the ICU setting and why?
    Metabolic alkalosis caused by excessive loop diuretic use. Bicarb can't be reabsorbed which decreases the plasma pH
  29. what is a potentially lethal drug interaction that may occur with thiazide use and why?
    Quinidine (hypokalemia and the reduced elimination of this drug)
  30. Major Steps of RAAS Cascade
    • Angiotensinogen (secreted by liver)-RENIN-Ang I-ACE-Ang II:
    • 1. adrenal (zonal glomerulosa)...ALDOSTERONE (inc. Na abs) acting @ TAL/LOH, DCT, CD
    • 2. PCT (inc Na abs)
    • 3. Efferent (VC/mant. GFR)
    • 4. Hypothalamus (thirst, inc. ADH secretion)
  31. 4 factors affecting JG cell activation of renin
    • 1. hypotension
    • 2. hypovolemia
    • 3. hyponatremia
    • 4. high sympathetic outflow
  32. aldosterone activation chain
    ang II, adrenal (zona glomerulosa), aldosterone (increased NaCl absorption) at TAL/LOH, DCT, CD
  33. Major FXN of RAAS
    regulation of TPR and blood volume via reabsorption mechanisms

    activation goal: to increase blood volume and TPR = increase blood pressure
  34. Renin is released by the JG cells in the walls of the afferent arteriole. The 3 places it works are:
    • 1. Intrarenal macula densa pathway: chemoreceptors sense low NaCl via transporter and increase renin release
    • 2. Intrarenal baroreceptor pathway: pressure receptors sense high pressure and decrease renin release
    • 3. Beta adrenergic pathway: an increase in SNS increases NE, which activates B1 receptors on JC cells, which increases renin ***this is why beta blockers decrease renin
  35. The short loop and long loop negative feedback of renin
    short: ang II binds to AT1 receptors causing inhibition of renin

    long: increased BP= increase RPP= decrease renin release.....increased baroreflex=decreased SNS= decreased NE= decreased renin release ***increase PNS!
  36. Ang II acts on 6 key areas:
    • 1. Vascular smooth muscle- VC arterial & venous
    • 2. Adrenal cortex- aldosterone release (high H2O/Na reabs & low K secretion)
    • 3. Kidney- efferent arteriole VC (high GFR, Pgc)
    • 4. CNS- Increase thirst and ADH (to inc. vol)
    • 5. SNS- pressure sensing**reset pressure threshold!
    • 6. CV structure- wall thickening/remodelling
  37. Therapeutic targets in RAAS
    (ultimate goal is prevent effects of Ang II= decrease VC, aldosterone secretion, ADH release)
    • ACE (Ang I to Ang II)
    • Renin (Angiotensinogen to Ang I)
    • AT1 receptor (Ang II to AT1 receptor)
  38. Normal end results of activated RAAS
    • *Na/H2O retention
    • *K/Mg loss
    • *CV remodelling
    • *decrease arterial compliance
    • *increase sensitive to catecholamines
  39. Secondary factors that regulate aldosterone secretion
    ACTH, K, Mg, vasopressin, serotonin, catecholamines, endothelin
  40. ACE inhibitors: MOA
    • 1) ACE cleaves the His-Leu off Ang I to create Ang II. ACEi prevent this cleavage.
    • 2) Prevent the degradation of Bradykinin

    *discovered via SA pit viper. 1st drug=Captopril
  41. Adverse effects of ACEi
    • 1. dry cough
    • 2. hyperkalemia (due to blocking of RAAS)
    •      a. k supp
    •      b. cv conditions
    •      c. renal insufficiency
    •      d. other RAAS blocking drugs!
    • 3. angioedema***must switch to CCB
    • 4. ARF (extra caution with NSAIDS)
  42. CI with ACEi
    • 1. renal artery stenosis
    • 2. angioedema
    • 3. black box- pregnancy ***blocking AT1 & AT2(cell growth and development)
  43. PK of ACEi
    minor P450

    **all cleared by kidney EXCEPT fosinopril (urinary and biliary route)
  44. Only ACEi with a sulfhydryl group
  45. Only ACEi that is crushable
  46. Only ACEi that is cleared both by urine and biliary routes
  47. ARB vs. ACEi
    ARB binds to AT1 receptor with high affinity/selectivity vs. AT2. This is important because ACE is not the only enzyme that can convert Ang I to Ang II. Binding AT1 ensures selective inhibition of Ang II, meaning ARBs do not affect bradykinin. 
  48. ARB: MOA
    by binding competitively to AT1, this forces Ang II to bind to AT2 receptors, which contributes to vasodilation.
  49. ARB: Uses
    • HT- all
    • Diabetic Neph- Irbesartan & Losartan
    • Stroke prophylaxis- Losartan
    • Heart Failure- Valsartan
  50. ARB: AE
    • *no dry cough
    • hyperkalemia (k supp, cv pts, renal insuff)
    • ARF (NSAID caution!)
    • **low risk angioedema, but put on CCB if prob
  51. ARB: CI
    • renal artery stenosis
    • angioedema (place on CCB)
    • black box- pregnancy cat d
  52. ARB: PK
    • minor P450
    • all eliminated by LIVER and KIDNEY
  53. Renin Inhibitors: what's so great about it?
    The ONLY FDA approved direct renin inhibitor= Aliskiren (Tekturna).

    Monotherapy or combo with diuretics and ARBs for Tx of HT.
  54. Renin inhibitor: MOA
    inhibits renin upstream of RAAS. **potential benefit and favorable AE profile.

    Inhibiting renin prevents cleavage of Angiotensinogen to Ang I, reducing both Ang I and Ang II levels.
  55. Renin Inhibitors: AE
    • *dose related GI
    • *dizziness
    • *fatigue
    • *Low incidence cough and angioedema
    • *headache
    • *hyperkalemia
    • *hypotension
    • *$$$
  56. Renin Inhibitors: CI
    • black box- preg D
    • angioedema (low risk, but there)
    • hyperkalemia
  57. Renin Inhibitors: PK
    • poor oral absorption
    • METABOLIZED by 3A4!!!!! (Drug-Drug: macrolides, a/depressants, a/fungal)
  58. Aldosterone Antags (K sparing): MOA
    ENaC on apical membrane of CD is affected by two ways. End result is inhibition of Na reabs and K excretion.
  59. 2 ways ENaC is inhibited by Aldosterone antagonists
    • 1. ENaC inhibitors (direct): TRIAM/AMILORIDE
    •  directly block reabsorption of NA on the apical side in the CD, which inactivates Na/K ATPase on basolateral side, so there is no K to be excreted on apical side
    • 2. Aldosterone antagonists (indirect): SPIRONOLACTONE/EPLERENONE prevents aldosterone from binding to eh mineralocorticoid receptor in the nucleus, which decreases expression of ENaC and Na/K ATPase
  60. Advantage of Eplerenone vs. Spironolactone
    Newer, more selective, less adverse effects

    **both of these drugs might cause Metabolic Acidosis (by blocking secretion of H along with K)
  61. Contraindications/AE with Spironolactone
    • Peptic Ulcers (use Eplerenone)
    • gynecomastia
  62. Uses of Spirinolactone vs. Eplerenone
    Spironolactone: HT, hyperaldost, edeme (heart failure), hypokalemia

    Eplerenone: HT, heart failure, post-MI, edema, hypokalemia, hyperaldosterone
  63. CCB's (general info)
    • *Critically involved in initiation of cardiac and smooth muscle contraction. (Sm musc.=IMPERMEABLE to Ca...increases with depolarization due to activation of VGCC)
    • *Involved in depol or nodal in heart (SA/AV)
    • *Required for fusion of synaptic vesicles w/in nerve terminal (NT release)
    • *subunits vary depending on location=targeting!
  64. Normal Calcium Channel activation
    Ca enters via VGCC, then binds to calmodulin. This complex activates MLCK, which phosporylates MLC. MLC-P binds to Actin and causes contraction. ***cGMP dephosphorylated MLC-P, leading to relaxation!
  65. CCB's and Vascular Smooth Muscle
    • EXTREMELY sensitive to voltage changes
    • Unlike cardiac and neuronal, VSM has RMP b/t -40 and -20. Therefore some VGCC are always open= Basal "tone".

    This can be regulated by altering K efflux as well as by cell surface receptors.
  66. What drug can regulate membrane voltage, causing a similar response/indirect effect as VGCC CCB's? How?
    Minoxidil (Vasodilator) promotes opening of ATP-modulated K channels. This hyperpolarizes the cell (more negative), decreasing VGCC activity, thus decreasing contractility
  67. 2 Classes of CCB's
    • 1. DHP (Nifedipine)
    • 2. non-DHP (Verapamil & Diltiazem)
  68. General Fx of CCBs on:
    1. SA node
    2. AV node
    3. Cardiac myocyte
    4. Coronary artery
    5. Peripheral veins
    6. Peripheral arterioles
    • 1. SA: decrease automaticity (rhythmic firing)
    • 2. AV: decrease conduction (velocity)
    • 3. Cardiac myo: decrease afterload/TPR, decrease myocardial O2 demand **ANGINA
    • 4. Coronary artery: vasodilation, increase O2 supply **ANGINA
    • 5. Peripheral veins: minimal VD
    • 6. Peripheral arterioles: vasodilation, decrease afterload, decrease myocardial O2 demand
  69. Cardioelectric review
    1. SA: primary pacemaker
    2. Atrial: expel blood
    3. AV: secondary pacemaker
    4. Purkinje fibers
    • SA: Ica, Ik, If
    • Atrial: Ina, Ica, Ik
    • AV: Ica, Ik, If
    • Purk
  70. CCB's on coronary arteries
    some vasal tone always present...CCB=vasodilation=increase O2 supply
  71. CCB's in peripheral arterioles
    vasodilation=decrease resistance=decreased O2 required
  72. CCB's in peripheral veins
    little effect (low # Ca channels vs. arteries)

    • venous return and preload stay the same
    • **F-S: lower SV with same preload moves curve RIGHT
  73. How are CCB's similar?
    • * They all require entry from the inner side of the membrane
    • * Binding is favored when the channel is in the depolarized state

  74. Differences in CCB's
    Verapamil and Diltiazem also prefer to bind to the INACTIVE state (These are non-DHP's=CV)

    • Therefore these are called "use-dependent" and means that they "promote the inactive state" (harder to move to active state)
    • More Cardiac Effects than DHPs.
  75. C/C CCBs
    • ALL decrease afterload
    • non-DHP's: - inotropic (contraction), -chrono/dromo (HR & Conduction), decrease afterload
    • DHP's: decrease afterload only
  76. Hemodynamic Fx of CCB's
    • Dilation of peripheral arteries: relax, decrease afterload, decrease O2 demand
    • Dilation of coronary arteries: relax, increase blood flow, increase O2 supply
  77. Cardiac effects of CCBs
    • Reduction of SA firing rate (dec. HR)
    • Reduction AV conduction (prolong PR)
    • Reduction cardiomyocyte contract (dec. CO)

    ***Most pronounced with Verapamil/Diltiazem
  78. At SAME preload, what is effect of positive and negative inotropic drug?
    • positive (Digoxin/B agonist)= move curve up
    • negative (CCB's)= move curve down

    no change in preload, just FOC
  79. CCB's: AE
    all are associated with drugs' MOA (contraction loss/relaxation)

    ex: constipation due to loss of GI motility

    lethargy/hypotension, bradycardia, av nodal block, decreased CO (with large decrease FOC)
  80. CCB's: PK
    Amlodipine & Felodipine are the ONLY agents that have QD dosing (long t1/2). All others require multiple dosing or SR.

    Verapamil (and lesser Diltiazem) are CYP3A4!
  81. CCB: Therapy
    • ALL: HT
    • Angina: Amlodipine, Nisoldipine, Nifedipine, Verapamil, Diltiazem
    • Raynaud's (circulatory): Some
    • A/arrhythmia/migraine: Verapamil
  82. Angina Pectoris
    "chest pain" esp. in womencharacterized by chest,jaw,shoulder,back,arm discomfort.Primary symptom of ischemic heart disease (aka myocardial ischemia)
  83. Mycardial ischemia
    results when heart experiences insufficient flow. Demand > SupplyProlonged ischemia = heart tissue damage
  84. "Referred Pain"
    when heart pain transmits to spine and cortex, adjacent nerves can pick up signals
  85. Angina Tx
    1. decrease O2 demand2. increase O2 supply3. 1&2 *VERAPAMIL
  86. When does O2 demand increase?
    1. increase HR2. increase in contractility3. increased venous  (F-S:increase VR=Inc. CO)
  87. What drugs to do we know that can decrease Oxygen demand?
    • 1. Beta Blockers
    • 2. CCB's (esp. verapamil and diltiazem)
  88. What reasons force coronary arteries to become unable to supply adequate blood flow to heart?
    • 1. atherosclerosis (tx: Statins)
    • 2. vasospasm (tx: Nitrates)
    • 3. microthrombotic events (tx: a/coag,a/plate)
  89. 3 classifications of angina
    • 1. Stable Angina (classical,typical,angina on exertion)
    • 2. Variant Angina (Prinzmetal's)
    • 3. Unstable Angina (UA, "angina at rest")
  90. Stable Angina
    • "angina on exertion"
    • typically present at 70-75% blockage
  91. Variant Angina

    caused by unpredictable, exercise independent vasospasms.
  92. Unstable Angina
  93. Organic nitrates: MOA 1
    1. sheer stress causes eNOS to convert arginine to NO. NO activates guanylyl cyclase, which converts GTP to cGMP. cGMP dephosphorylates MLC-P to MLC, causing relaxation.
  94. Organic Nitrates: MOA 2
    NO diffuses freely across VSM membrane and binds to heme moiety on an enzyme called soluble guanylyl cyclase (sGC) and activates it. sGC converts GTP to cGMP, causing dephos of MLC-P to MLC, causing relaxation.
  95. Low dose vs. High dose Nitrates
    Low dose: primarily venous fx (opposite CCB!) & decrease O2 demand*increase venous capacitance*decrease venous return*little change in arterial BPHigh dose: also affects arteries (inc. O2 supply)*increased coronary artery blood flow
  96. Drug tolerance to nitrates
    denitrated to NO by mitochondrial aldehyde dehydrogenase (mtALDH). prolonged exposure to nitrates leads to damage of mtALDH. this decreases bioactivation of drug and necessitates a "nitrate-free" period **usually occurs w/in 48-72 hours
  97. "nitrate-free" period and therapy
    • *non-symmetrical dosing intervals (7,noon,5/ 8,2)
    • *long acting QD in am, remove at night
    • *do not use with PDEi=DECREASE BP!
  98. 3 preparations of nitrates
    • 1. Nitroglycerin- SL, spray (bypass 1st pass); TD ointment (6-8 hrs then wipe off); TD patch (24hr, remove HS); ER cap; IV
    • 2. ISDN- oral & chew tabs; longer acting than nitroglycerin
    • 3. ISMN- oral tabs & caps; longer acting than ISDN **QD
  99. Special considerations with nitrates
    • 1. Extensive liver metabolism of ISDN
    • 2. Tolerance development (mtALDH)
    • 3. Absolute CI with PDE-5i
    • 4. SL preps extremely fast acting/short duration
    • 5. Protect nitroglycerin from light, air, heat, moisture. USE ORIGINAL container. Relplace unopened (6 mo) and opened (2 mo.). HANDLE AS LITTLE AS POSSIBLE
  100. Ranolazine (RANEXA)
    • 2nd line nitrate as add on therapy for those unresponsive to B Block, CCB's, or nitrates alone. Similar to ion channel blocking of AMIODARONE.
    • 3A4 metab and PGP substrate...USE CAUTION WITH VERAPAMIL
  101. Direct Acting Vasodilators
    • *Reserved for refractory HT/emergencies.
    • *Hydralazine/ISDN has been shown to be very effective in Tx heart failure in African Americans.
    • *Primarily affect arterial vasc.
    • **Potent afterload  reducers.
    • *Nitroprusside= also venodilation.
    • *May elicit significant SNS activation and reduce sodium excretion due to low renal BF and low renin **co-administer with B blocker and diuretic
  102. Direct VD: Minoxidil
    • Opens Katp channels in VSM, leading to hyperpolarization (**also a target for Diabetic drugs)
    • **Potent VD "Last-line antihypertensive"
    • AE: edema (use diuretic), tachycardia (B Blocker), significant hirusitism
  103. Direct VD: Hydralazine
    • MOA unkown. Maybe opening of K channels or inhibiting IP3 mediated calcium release.
    • **reduces development of nitrate tolerance. Used in combo for advanced heart failure.High bioavailability. slow acetylators are susceptible. Lupus-like symptoms rare and reversible
  104. Direct VD: Sodium Nitroprusside
    • Activates GC, leading to cGMP and relaxation.
    • *Potent arterial and venous dilator. Used in HT emergencies and SEVERE heart failure.
    • *Contains cyanide..metabolized to thiocyanate and slowly excreted by kidney. TOXIC. 
    • Facilitate excretion with sodium thiosulfate (sulfur donor)
  105. 3 Major differenced between nitrates and nitroprusside:
    NP: no bioactivation, arteries and veins, lower tolerance risk.

    ON: requires bioactivation, veins only, needs "nitrate-free" period.
  106. PDE-5 inhibitors
    • PDE breaks down cGMP. PDE-5 is selective for penile area. PDE-5 inhibitors prevent breakdown of cGMP to promote vasodilation.
    • *Sildenafil may inhibit PDE-6 in high doses (retina).
    • ALL 3 are 3A4!
Card Set:
Pharm Sci 1 test 1
2013-10-07 00:51:28
MSOP pharm sci

Show Answers: